Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer

Modern Pathology

Volumn 23, Issue 1, 2010, Pages 62-70

  Moelans, Cathy B ^a   De Weger, Roel A ^a   Van Blokland, Marja Tm ^a   Van Der Wall, Elsken ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; HER2; In situ hybridization; Multiplex ligation dependent probe amplification; TOP2A; TopoIIa

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOSS; GENE OVEREXPRESSION; GENE PROBE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; VALIDATION STUDY;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 73949150777     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.136     Document Type: Article

References (46)

1. Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase II. Nature 1996;379:225-232.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
7. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24:2428-2436.
8. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophospha-mide, methotrexate, and fluorouracil or cyclopho-sphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-7490.
9. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophospha-mide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116.
10. Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclopho-sphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by doc-etaxel and trastuzumab (ACTH) with docetaxel, carbo-platin and trastuzumab (TCH) in Her2-positive early breast cancer patients: BCIRG006 study. [abstract]. Breast Cancer Res Treat 2005;94:S5, 2005 (Suppl 1; abstract 1).
11. Mano MS, Rosa DD, de AE, et al. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64-77.
12. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8: 1061-1067.
13. Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26: 736-744.
14. Di Leo A, Biganzoli L, Claudino W, et al. Topoisome-rase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer 2008;44:2791-2798.
15. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant an-thracycline-based chemotherapy. Eur J Cancer 2004;40:205-211.
16. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001;12: 1081-1089.
17. Jarvinen TA, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77: 2267-2273.
18. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
19. Asano T, Kleinerman ES, Zwelling LA, et al. Adeno-virus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells. Acta Oncol 2005;44:240-247.
20. Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-734.
21. Durbecq V, Paesmans M, Cardoso F, et al. Topoisome-rase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004;3: 1207-1214. (Pubitemid 39440165)
22. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39: 288-297.
23. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
24. Purnomosari D, Aryandono T, Setiaji K, et al. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/ neu amplification in invasive breast cancer. Biotech Histochem 2006;81:79-85.
25. Moelans CB, de Weger RA, van Blokland MT, et al. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol 2009;31:1-10.
26. Packeisen J, Korsching E, Herbst H, et al. Demysti-fied.tissue microarray technology. Mol Pathol 2003;56:198-204.
27. Moerland E, van Hezik RL, van der Aa TC, et al. Detection of HER2 amplification in breast carcinomas: comparison of Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence In situ Hybridization (FISH) combined with automated spot counting. Cell Oncol 2006;28:151-159.
28. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
29. Garcia-Caballero T, Menendez MD, Vazquez-Boquete A, et al. HER-2 status determination in breast carcinomas. A practical approach. Histol Histopathol 2006;21:227-236.
30. Dandachi N, Dietze O, Hauser-Kronberger C. Chromo-genic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002;82:1007-1014.
31. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-154.
32. Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 2005;58:710-714.
33. Dolan M, Snover D. Comparison of immunohistochem-ical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol 2005;123:766-770.
34. Marla S, Roxburgh P, Burton P, et al. HER2 positive early breast cancers: tumour demographics and trastu-zumab therapy in the real-world [abstract]. Cancer Res 2009;69(Suppl 2):11.
35. Olsen KE, Knudsen H, Rasmussen BB, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35-42.
36. Jarvinen TA, Tanner M, Barlund M, et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150.
37. Bhargava R, Lal P, Chen B. HER-2/neu and topoisome-rase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123:889-895.
38. van de Vijver M, Bilous M, Hanna W. Chromogenic in-situ hybridisation (CISH) compared with FISH and IHC for detection of HER2 gene amplification: an international validation ring study [abstract]. Breast Cancer Res Treat 2003;82:S75 (suppl 1, abstract 324).
39. Lewis F, Jackson P, Lane S, et al. Testing for HER2 in breast cancer. Histopathology 2004;45: 207-217.
40. Paik S, Kim C, Jeong J. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31 [abstract]. Proc Am Soc Clin Oncol 2007;25(Suppl 18):511.
41. Moelans CB, de Weger RA, Ezendam C, et al. HER-2/ neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual-and laser microdissection. BMC Cancer 2009;9:4.
42. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644-650.
43. Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 2009;101:615-618.
44. Troxell ML, Bangs CD, Lawce HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006;126:709-716.
45. Yeh I-T, Martin M, Robetorye R, et al. 'Polysomy 17' by FISH for HER2 in breast cancer is a misnomer: results of chromosome 17 analysis by array comparative genomic hybridization [abstract]. Cancer Res 2009;69 (Suppl 2):11.
46. Kauraniemi P, Kuukasjarvi T, Sauter G, et al. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003;163:1979-1984.